- Home
- MDXH vs XGN Comparison
MDXH vs XGN Comparison
Compare MDXH & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- XGN
- Stock Information
- Founded
- MDXH 2003
- XGN 2002
- Country
- MDXH Belgium
- XGN United States
- Employees
- MDXH N/A
- XGN N/A
- Industry
- MDXH
- XGN Medical Specialities
- Sector
- MDXH
- XGN Health Care
- Exchange
- MDXH Nasdaq
- XGN Nasdaq
- Market Cap
- MDXH 93.1M
- XGN 86.6M
- IPO Year
- MDXH 2021
- XGN 2019
- Fundamental
- Price
- MDXH $1.86
- XGN $3.58
- Analyst Decision
- MDXH Strong Buy
- XGN Strong Buy
- Analyst Count
- MDXH 2
- XGN 2
- Target Price
- MDXH $7.00
- XGN $7.50
- AVG Volume (30 Days)
- MDXH 58.0K
- XGN 154.7K
- Earning Date
- MDXH 02-26-2025
- XGN 03-17-2025
- Dividend Yield
- MDXH N/A
- XGN N/A
- EPS Growth
- MDXH N/A
- XGN N/A
- EPS
- MDXH N/A
- XGN N/A
- Revenue
- MDXH $84,708,000.00
- XGN $55,751,000.00
- Revenue This Year
- MDXH $28.76
- XGN $7.13
- Revenue Next Year
- MDXH $19.91
- XGN $19.14
- P/E Ratio
- MDXH N/A
- XGN N/A
- Revenue Growth
- MDXH 33.01
- XGN 8.00
- 52 Week Low
- MDXH $1.55
- XGN $1.30
- 52 Week High
- MDXH $3.85
- XGN $6.22
- Technical
- Relative Strength Index (RSI)
- MDXH 41.65
- XGN 38.58
- Support Level
- MDXH $1.82
- XGN $3.63
- Resistance Level
- MDXH $2.01
- XGN $4.55
- Average True Range (ATR)
- MDXH 0.09
- XGN 0.50
- MACD
- MDXH 0.01
- XGN -0.13
- Stochastic Oscillator
- MDXH 46.43
- XGN 2.75
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.